Inhibitors to clotting factors

Area of Science:

• Hematology
• Immunology
• Biochemistry

Background:

• Clot formation involves plasma proteins, fibrinogen conversion, and fibrin cross-linking by factor XIII.
• Deficiencies or abnormalities in coagulation factors lead to bleeding disorders.
• Natural inhibitors (e.g., antithrombin III, protein S, protein C) regulate clotting.

Purpose of the Study:

• To review acquired inhibitors of coagulation factors, also known as circulating anticoagulants.
• To differentiate between alloantibodies (in congenital deficiencies) and autoantibodies (spontaneous formation).
• To discuss antiphospholipid antibodies separately due to their distinct clinical presentations.

Main Methods:

• Review of literature on acquired coagulation inhibitors.
• Classification of inhibitors based on their origin (alloantibodies vs. autoantibodies).
• Discussion of antibody targets (isolated factors vs. multiple proteins).

Main Results:

• Acquired inhibitors are antibodies that neutralize specific clotting proteins.
• Antibodies against isolated factors (e.g., factor VIII, IX) typically cause bleeding.
• Antiphospholipid antibodies can target multiple proteins and may cause thrombosis or be asymptomatic.

Conclusions:

• Acquired inhibitors represent a distinct category from natural inhibitors.
• Understanding the type of inhibitor (allo- vs. autoantibody) is crucial for diagnosis and management.
• Antiphospholipid antibodies present a unique clinical spectrum, including thrombosis.